Filing Flows › Amphastar Pharmaceuticals (AMPH) › Gross margin
Amphastar Pharmaceuticals (AMPH) gross margin by quarter
Amphastar Pharmaceuticals' gross margin was 48.0% in Q3 2026 (third quarter 2026), -2.8 pts from Q2 2026. Over the last 7 quarters it ranged from 41.1% (Q1 2026) to 51.4% (Q3 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 48.0% | -2.8 pts | -3.4 pts |
| Q2 2026 | 50.8% | +9.7 pts | +1.2 pts |
| Q1 2026 | 41.1% | -5.7 pts | -8.9 pts |
| Q4 2025 | 46.8% | -4.6 pts | — |
| Q3 2025 | 51.4% | +1.8 pts | — |
| Q2 2025 | 49.6% | -0.4 pts | — |
| Q1 2025 | 50.0% | — | — |
Q3 2026 at a glance
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amphastar Pharmaceuticals' gross margin?
Amphastar Pharmaceuticals' gross margin was 48.0% in Q3 2026 (third quarter 2026), -2.8 pts from Q2 2026.
How has Amphastar Pharmaceuticals' gross margin changed?
Over the last 7 quarters it ranged from 41.1% (Q1 2026) to 51.4% (Q3 2025).
Q3 2026 results → · How Amphastar Pharmaceuticals makes money →